An article in the New England Journal of Medicine asks whether settlements such as the $3 billion GlaxoSmithKline agreed to last July regarding off-label marketing of Paxil and Wellbutrin are sufficient to change corporate behavior, and proposes possible improvements to the system.
Outterson, J. “Punishing Health Care Fraud – Is the GSK Settlement Sufficient?
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.